Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ezabenlimab by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...
Ezabenlimab by Boehringer Ingelheim International for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
Ezabenlimab by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Colorectal Cancer. According to...
Ezabenlimab by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Oral Cavity (Mouth) Cancer. According...